Molecular Templates, Inc.
9301 Amberglen Blvd, Ste 100
Austin
TX
78729
United States
Tel: 512-869-1555
Website: http://mtem.com/
Email: careers@mtem.com
About Molecular Templates, Inc.
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development. Additional information about MTEM can be obtained at www.mtem.com.
OWNERSHIP: Public
STOCK SYMBOL: MTEM
STOCK EXCHANGE: NASDAQ
96 articles about Molecular Templates, Inc.
-
Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting
4/12/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported that three posters featuring data on its pipeline programs and technology platform will be presented at the AACR Virtual Annual Meeting I , taking place April 10-15, 2021.
-
Molecular Templates to Prioritize Next-Generation ETB Candidates
4/5/2021
Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma
-
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results
3/18/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2020.
-
Molecular Templates to Participate in Upcoming Virtual Investor Conferences - Feb 26, 2021
2/26/2021
Molecular Templates, Inc. announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.
-
Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering
2/18/2021
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $12.65 per share.
-
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
2/17/2021
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it has commenced an underwritten public offering of its common stock.
-
Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.
-
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology
1/19/2021
Dosing in Phase 1 Study in Subjects with PD-L1-Positive Cancers Expected to Start in 2Q21
-
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
12/21/2020
Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached
-
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
11/16/2020
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will deliver presentations and participate in 1on1 meetings at the Stifel 2020 Virtual Healthcare Conference
-
Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
11/5/2020
Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, reported financial results for the third quarter of 2020 and an update on its clinical pipeline.
-
Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results
8/6/2020
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2020.
-
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility
7/20/2020
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it has raised gross proceeds of approximately $43 million through its At-the-Market facility (“ATM”) with participation based on interest received from Consonanc
-
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform
6/22/2020
Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time
-
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II
5/15/2020
Abstracts feature data on ETBs against clinically validated targets including PD-L1, CTLA-4, SLAMF7 and CD45
-
Molecular Templates to Participate in Two May 2020 Virtual Investor Conferences
5/13/2020
Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, announced that management will participate in the Bank of America Securities Virtual Healthcare Conference and the UBS Virtual Healthcare Conference.
-
Molecular Templates, Inc. Reports First Quarter 2020 Financial Results
5/11/2020
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2020.
-
Molecular Templates, Inc. Announces that the 2020 Annual Meeting of Stockholders Will be Held in Virtual Format
5/7/2020
Molecular Templates, Inc. announced that the 2020 Annual Meeting of Stockholders will be held virtually due to the public health impact of the novel coronavirus outbreak and to support the health and well-being of the Company’s management and stockholders.
-
Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results
3/12/2020
Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies, reported financial results for the fourth quarter of 2019.
-
Molecular Templates to Present at Three March Investor Conferences
2/28/2020
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that management will present a corporate overview at the Cowen & Company 40th Annual Health Care Conference,